While clinically validated tests have been approved as companion diagnostics for poly(ADP)ribose polymerase (PARP) inhibitors in OC and other tumor types in the US (9), currently, CA-125 is the only blood-borne marker recommended for the diagnosis and management of OC, which has been validated in numerous studies (10). The gene discussed is MUC16; the disease is neoplasm.